
|Videos|March 4, 2020
A 60-Year Old Man With Untreated Stage IV EGFR-Mutated Non-Small Cell Lung Cancer
A 60-Year Old Man With Untreated Stage IV EGFR-Mutated Non-Small Cell Lung Cancer
Advertisement
Case: A 60-Year-Old Male with Untreated Stage IVEGFR+NSCLC
Initial presentation
- A 60-yearold Caucasian man presented with shortness of breath, mild dry cough
- PMH: hyperlipidemia, hypertension, medically controlled
- SH: non-smoker, worked 40 years in ship-building industry
- PE: Lungs clear on auscultation bilaterally; anxious-appearing; acknowledges feeling nervous about his health
Clinical workup
- Imaging:
- Chest x-ray showed a right bronchial lung mass
- Chest/abdomen/pelvic CT scan revealed a 4.6-cm mass on the right main bronchus and ipsilateral subcarinal lymphadenopathy; positive for a single suspicious 2-cm hepatic lesion on the right lobe
- PET scan showed activity in the right main bronchus and subcarinal nodal area, hepatic lesion was shown to be avid
- Brain MRI negative for metastases
- Patient underwent bronchoscopy with TBNA
- Diagnosis and staging: Biopsy showed high-grade lung adenocarcinoma; T2N2M1b IVA
- Molecular testing:EGFRexon 21 L858R, PD-L1 TPS 50%
- ECOG PS 0
Treatment
- Patient started on osimertinib 80 mg PO qDay
- At 3-week follow-up the patient had been tolerating treatment well; continued osimertinib
- Repeated chest/abdomen/pelvic CT with contrast after every 2 cycles,
- Partial response after 4 cycles, no disease progression at 3, 6 and 12 months
- Imaging at 19-month follow-up revealed a new solitary liver lesion
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































